Claims
- 1. A labeled compound according to formula I:
- 2. A compound according to claim 1 wherein the label is selected from 2H, 3H, 11C, 13C, 14C, 125I and 131I.
- 3. A compound according to claim 1 wherein the label is 3H.
- 4. A compound according to claim 1 wherein the label is 11C.
- 5. A compound according to claim 1 wherein the label is 14C.
- 6. A compound of claim 1 which is 1-Methyl-cyclohexanecarboxylic acid {(1R)-1-cyclohexylmethyl-2-[4-(2methoxyphenyl)-piperazin-1-yl]-ethyl}-amide; and pharmaceutically acceptable acid addition salts thereof.
- 7. A compound of claim 1 which is [Methoxy-3H]-1-Methyl-cyclohexane-carboxylic acid {(1R)-1-cyclohexylmethyl-2-[4-(2methoxyphenyl)-piperazin-1-yl]-ethyl}-amide, or a pharmaceutically acceptable addition salt thereof.
- 8. A compound of claim 1 which is [Methoxy-11C]-1-Methyl-cyclohexane-carboxylic acid {(1R)-1-cyclohexylmethyl-2-[4-(2methoxyphenyl)-piperazin-1-yl]-ethyl}-amide or a pharmaceutically acceptable acid addition salt thereof.
- 9. A method of treating a patient suffering from a chronic condition resulting from the dysfunction of the serotonergic 5-HT1A system comprising providing a therapeutically effective amount of compound of Formula I
- 10. A method of claim 9 wherein the dose is administered no more than once during a ten day period.
- 11. A method of claim 9 wherein the dose is administered no more than once during a fourteen day period.
- 12. The method of claim 9 wherein the CNS disorder is schizophrenia, paranoia or mano-depressive illness.
- 13. The method of claim 9 wherein the CNS disorder is a cognitive disorder.
- 14. The method of claim 9 wherein the CNS condition is anxiety.
- 15. The method of claim 9 wherein the CNS disorder is chronic pain, Parkinson's disease, Tourette's syndrome, autism, attention deficit disorder, hyperactivity disorders, stroke, treatment of eating disorders, sexual dysfunction, sleep disorders, social phobias, thermoregulatory disorders, endocrine disorders, urinary incontinence, vasospasm, prostate cancer, and treatment of alcohol and drug withdrawal.
- 16. The method of claim 9 wherein the patient is a human.
- 17. A method of potentiating the action of an inhibitor of serotonin reuptake comprising administering to a patient in need thereof in combination with a compound of Formula I
- 18. The method of claim 17 wherein the inhibitor of serotonin reuptake is fluoxetine, venlafaxine, duloxetine, sertraline, paroxetine, fluvoxamine, nefazodone, and mirtazapine.
- 19. A method of testing the effects of long term 5-HT1A receptor occupancy in a population of cells comprising contacting said cells with a labeled compound of Formula I
- 20. The method of claim 19 wherein the compound of Formula I is radiolabelled.
- 21. The method of claim 19 wherein the label is 2H, 3H, 11C, 13C, 14C, 125I, or 131I.
- 22. The method of claim 19 wherein the label is 3H.
- 23. The method of claim 19 wherein the label is 11C.
- 24. The method of claim 19 wherein the label is 14C.
- 25. The method of claim 19 wherein the cells are in vivo.
- 26. The method of claim 19 wherein the cells are in vitro.
- 27. A pharmaceutical composition comprising a compound of Formula I
- 28. The composition of claim 27 wherein the inhibitor of serotonin reuptake is fluoxetine, venlafaxine, duloxetine, sertraline, paroxetine, fluvoxamine, nefazodone, and mirtazapine
Parent Case Info
[0001] This application claims priority from co-pending provisional application serial No. 60/281,542, filed on Apr. 4, 2001, the entire disclosure of which is hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60281542 |
Apr 2001 |
US |